1 Story in coverage 0 Programs 0 Registered trials DEF 14A Sep 18 Latest SEC filing, period to Nov 2 Jul 23 Latest story
Timeline 1 Pipeline 0 Trials 0
Details
Headquarters Burlington, MA Incorporated Australia Industry Pharmaceutical Preparations Formerly BIONOMICS LIMITED/FI (to 2024) Also known as BIONOMICS LIMITED/FI, NEUP How the company describes itself Scancell Holdings plc develops targeted, off-the-shelf active immunotherapies using ImmunoBody and Moditope platforms to stimulate anti-tumor responses. Lead program iSCIB1+ is in Phase 2 for melanoma; Modi-1 is in Phase 2 for head and neck and renal cancers. The company's subsidiary GlyMab Therapeutics advances antibodies targeting tumor-specific glycans. source
